JonesResearch analyst Justin Walsh initiated coverage of Prime Medicine with a Buy rating and $20 price target. Prime is a preclinical stage biotechnology company developing a broad pipeline of potentially curative gene therapy assets that make use of prime editing technology developed by Dr. Liu, Dr. Anzalone, and Dr. Liu’s laboratory at the Broad Institute, the analyst tells investors in a research note. The firm believes the market is not fully appreciating and pricing in the potential within the company’s broader pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRME:
- Cathie Wood’s ARK Investment bought 141.7K shares of Prime Medicine today
- Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
- MaxCyte signs strategic platform license with Prime MedicinePrime Medicine
- Prime Medicine initiated with a Buy at Guggenheim
Questions or Comments about the article? Write to editor@tipranks.com